Matthew D. Hellmann

4 ta ish

Memorial Sloan Kettering Cancer Center

1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

   Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa +45

   Maqola20175 iqtibos

   ABIABI:AkademIndex/2026.other.339917

2. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

   Edward B. Garon, Naiyer A. Rizvi, Rina Hui +24

   Maqola20153 iqtibos

   ABIABI:AkademIndex/2026.other.577441

3. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

   Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.102835

4. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

   Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro +23

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.826278